Abstract
CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have